The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multimodal biomarkers overcome sampling bias to predict presence of aggressive localized prostate cancer.
 
David Monty Berman
Honoraria - Bayer; Janssen Oncology
Consulting or Advisory Role - Janssen Oncology
Patents, Royalties, Other Intellectual Property - patented methylation based biomarker for detection of prostate cancer
Travel, Accommodations, Expenses - Janssen Oncology; Thermo Fisher Scientific
(OPTIONAL) Uncompensated Relationships - Thermo Fisher Scientific
 
Anna YW Lee
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
 
Robert Lesurf
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
 
Palak Patel
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
 
Walead Ebrahimizadeh
No Relationships to Disclose
 
Jane Bayani
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
(OPTIONAL) Uncompensated Relationships - Thermo Fisher Scientific
 
Nadia Boufaied
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
 
Tamara Jamaspishvili
No Relationships to Disclose
 
Karl-Philippe Guerard
No Relationships to Disclose
 
Dan Dion
No Relationships to Disclose
 
Laura A Lee
No Relationships to Disclose
 
Vasundara Venkateswaran
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
 
Simone Chevalier
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
 
Fadi Brimo
No Relationships to Disclose
 
Ralph Buttyan
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
 
Axel A Thomson
Employment - Zonula
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
 
Paul C Park
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
 
Jacques Lapointe
Patents, Royalties, Other Intellectual Property - Fight Against Cancer Innovation Trust
 
Paul Christopher Boutros
Consulting or Advisory Role - BioSymetrics
Patents, Royalties, Other Intellectual Property - Holds patents on multiple biomarkers
 
John Bartlett
Honoraria - bioTheranostics; NanoString Technologies; Oncology Education
Consulting or Advisory Role - BioNTech; bioTheranostics; Insight Genetics; oncoXchange; Pfizer; RNA Diagnostics
Research Funding - Agendia; bioTheranostics; Genoptix; NanoString Technologies; Stratifyer GmbH; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Invention Disclosure Name: A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer Date: 21/08/2019; John Bartlett currently has 5 pending patents: 1. Jan 2017: Methods and Devices for Predicting Anthracycline Treatment Efficacy, US utility – 15/325,472; EPO – 15822898.1; Canada – not yet assigned 2. Jan 2017: Systems, Devices and Methods for Constructi (Inst)
Travel, Accommodations, Expenses - bioTheranostics; NanoString Technologies